Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.942 EUR | +0.45% | +1.61% | -18.56% |
Business Summary
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Number of employees: 14,484
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 1,296,163 | 100.0 % | 1,518,619 | 100.0 % | +17.16% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
43.0
%
| 537,452 | 41.5 % | 652,441 | 43.0 % | +21.40% |
Established Markets
23.6
%
| 315,162 | 24.3 % | 358,407 | 23.6 % | +13.72% |
Japan
17.3
%
| 258,758 | 20.0 % | 262,303 | 17.3 % | +1.37% |
International
9.5
%
| 110,081 | 8.5 % | 144,735 | 9.5 % | +31.48% |
Greater China
5.3
%
| 66,305 | 5.1 % | 80,011 | 5.3 % | +20.67% |
Other
1.4
%
| 8,406 | 0.6 % | 20,722 | 1.4 % | +146.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 01/86/01 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | 01/11 |
Kenji Yasukawa
CHM | Chairman | 63 | 01/86/01 |
Compliance Officer | - | 01/22/01 | |
Chief Tech/Sci/R&D Officer | - | - | |
Chief Tech/Sci/R&D Officer | - | - | |
Director/Board Member | 65 | 01/06/01 | |
Noriyuki Uematsu
BRD | Director/Board Member | 63 | 01/16/01 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 01/83/01 |
Atsushi Kamide
IRO | Public Communications Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 63 | 01/86/01 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 01/86/01 |
Tatsuro Ishizuka
BRD | Director/Board Member | 68 | 01/19/01 |
Eriko Sakurai
BRD | Director/Board Member | 63 | - |
Director/Board Member | 65 | 01/06/01 | |
Hiroko Sakai
BRD | Director/Board Member | 63 | 01/83/01 |
Hiroo Sasaki
BRD | Director/Board Member | 68 | 01/18/01 |
Hiroshi Kawabe
BRD | Director/Board Member | 72 | 01/19/01 |
Mika Nakayama
BRD | Director/Board Member | - | - |
Compliance Officer | - | 01/22/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,809,663,075 | 1,788,505,828 ( 98.83 %) | 16,561,677 ( 0.9152 %) | 98.83 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
8,333,333 | 8.64% | 17,083,333 $ | |
7,266,342 | 3.89% | 16,712,587 $ | |
ASTELLAS PHARMA INC. 0.04% | 731,000 | 0.04% | 7,032,907 $ |
FIBROGEN, INC. 5.03% | 4,968,367 | 5.03% | 5,067,734 $ |
ONCOLYS BIOPHARMA INC. 3.57% | 727,200 | 3.57% | 3,211,664 $ |
Company contact information
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho Chuo-Ku
103-8411, Tokyo
+81 3 3244 3000
http://www.astellas.comGroup companies
Name | Category and Sector |
---|---|
Astellas BV
Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands. |
Financial Conglomerates
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.51% | 728B | |
+33.05% | 603B | |
-6.23% | 360B | |
+18.78% | 332B | |
+1.35% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.19% | 164B |
- Stock Market
- Equities
- 4503 Stock
- YPH Stock
- Company Astellas Pharma Inc.